These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32945574)

  • 1. Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
    Kusnadi EP; Trigos AS; Cullinane C; Goode DL; Larsson O; Devlin JR; Chan KT; De Souza DP; McConville MJ; McArthur GA; Thomas G; Sanij E; Poortinga G; Hannan RD; Hannan KM; Kang J; Pearson RB
    EMBO J; 2020 Nov; 39(21):e105111. PubMed ID: 32945574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
    Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.
    Woods SJ; Hannan KM; Pearson RB; Hannan RD
    Biochim Biophys Acta; 2015 Jul; 1849(7):821-9. PubMed ID: 25464032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
    Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
    Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
    Bursać S; Prodan Y; Pullen N; Bartek J; Volarević S
    Trends Cancer; 2021 Jan; 7(1):57-76. PubMed ID: 32948502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
    Chan JC; Hannan KM; Riddell K; Ng PY; Peck A; Lee RS; Hung S; Astle MV; Bywater M; Wall M; Poortinga G; Jastrzebski K; Sheppard KE; Hemmings BA; Hall MN; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Sci Signal; 2011 Aug; 4(188):ra56. PubMed ID: 21878679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
    Negi SS; Brown P
    Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
    Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
    Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Myc overexpression increases ribosome biogenesis and protein synthesis independent of mTORC1 activation in mouse skeletal muscle.
    Mori T; Ato S; Knudsen JR; Henriquez-Olguin C; Li Z; Wakabayashi K; Suginohara T; Higashida K; Tamura Y; Nakazato K; Jensen TE; Ogasawara R
    Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E551-E559. PubMed ID: 34423683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance.
    El Hassouni B; Sarkisjan D; Vos JC; Giovannetti E; Peters GJ
    Curr Med Chem; 2019; 26(33):6020-6032. PubMed ID: 30501594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel inhibitors of ribosome biogenesis by innovative high throughput screening strategies.
    Scull CE; Zhang Y; Tower N; Rasmussen L; Padmalayam I; Hunter R; Zhai L; Bostwick R; Schneider DA
    Biochem J; 2019 Aug; 476(15):2209-2219. PubMed ID: 31341008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of mesothelioma is driven by a dysregulated translatome.
    Grosso S; Marini A; Gyuraszova K; Voorde JV; Sfakianos A; Garland GD; Tenor AR; Mordue R; Chernova T; Morone N; Sereno M; Smith CP; Officer L; Farahmand P; Rooney C; Sumpton D; Das M; Teodósio A; Ficken C; Martin MG; Spriggs RV; Sun XM; Bushell M; Sansom OJ; Murphy D; MacFarlane M; Le Quesne JPC; Willis AE
    Nat Commun; 2021 Aug; 12(1):4920. PubMed ID: 34389715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.
    Musso L; Mazzini S; Rossini A; Castagnoli L; Scaglioni L; Artali R; Di Nicola M; Zunino F; Dallavalle S
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):615-629. PubMed ID: 29229300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate.
    Scala F; Brighenti E; Govoni M; Imbrogno E; Fornari F; Treré D; Montanaro L; Derenzini M
    Oncogene; 2016 Feb; 35(8):977-89. PubMed ID: 25961931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
    Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
    FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
    Hein N; Cameron DP; Hannan KM; Nguyen NN; Fong CY; Sornkom J; Wall M; Pavy M; Cullinane C; Diesch J; Devlin JR; George AJ; Sanij E; Quin J; Poortinga G; Verbrugge I; Baker A; Drygin D; Harrison SJ; Rozario JD; Powell JA; Pitson SM; Zuber J; Johnstone RW; Dawson MA; Guthridge MA; Wei A; McArthur GA; Pearson RB; Hannan RD
    Blood; 2017 May; 129(21):2882-2895. PubMed ID: 28283481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
    Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
    Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.